chmuse
Member
One of the current dramas in the peptide world is how a seller got their hands on this peptide everyone wanted, but no one else was willing to sell. Turns out it's because it degrades so terribly in transportation, and anyone who'd done any amount of research should have realized this. Instead everyone is out money and everyone's pissed about it.This is always my first thought with any pharma product that made it passed costly initial development. and was canned when testing started.
80% of peptide drugs fail at a late stage, sometimes as late as the first human injection.
People don't realize the intense scrutiny these protein drugs must be put under.
"In silico" testing, where the predict every potential thing that can go wrong, degradation, aggregation, manufacturing by products, and each of those proteins is checked to estimate its potential harm,
If one thing changes, 1 degree of temperature in the manufacturing room, a different stopper material in the vial, it's got to be checked again for potentially new proteins that can form.
AAS are like bricks, these are microchips by comparison.
Sometimes there's no researching happening at all, just "this person I see posting a lot says it's great, so now I want to try it!"


